Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somaxon's Silenor Could Switch OTC In Five To Seven Years

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite a "clear path" from FDA for the insomnia drug, the firm will need to conduct efficacy, safety and label comprehension studies, and may use a lower-than-Rx dose.
Advertisement

Related Content

Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales

Topics

Advertisement
UsernamePublicRestriction

Register

PS072980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel